- Thinly traded nano cap VistaGen Therapeutics (NASDAQ:VTGN) is up 10% premarket on light volume following its announcement that the last participant has completed dosing in its Phase 2 ELEVATE clinical trial evaluating AV-101 for the adjunctive treatment of major depressive disorder (MDD). Topline results should be available before year-end.
VistaGen up 10% premarket on advancement of AV-101 in MDD
Recommended For You
More Trending News
About VTGN Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
VTGN | - | - |
Vistagen Therapeutics, Inc. |